News Archive

GELCLAIR Now Available

GELCLAIR Now Available

Find out how to order Gelclair by clicking on the link above.

Living with Triple Negative Breast Cancer: TENACIOUS WOMEN

Living with Triple Negative Breast Cancer: TENACIOUS WOMEN

April 24, 2017: 45 year old Keryn Barnett never really knew what she wanted to do with her life in terms of a career. While always employed, she was missing what she thought was her true calling. It was only after being diagnosed with triple-negative breast cancer in late 2014 and her subsequent treatment, that the answer finally dawned. She is now in her second year of a four-year university course, training to become a radiation therapist. She will soon be helping other cancer patients “and this time it will be them getting zapped, not me!”

Julie's Ordeal with Oropharyngeal Cancer and Oral Mucositis

Julie's Ordeal with Oropharyngeal Cancer and Oral Mucositis

Accomplished Australian journalist and broadcaster Julie McCrossin had frequently hosted and entertained medical professionals at major international cancer conferences. Then she was diagnosed with Stage 4 oropharangeal cancer that had spread to her lymph nodes. She endured chemotherapy and radiation therapy which saved her life, but caused debilitating oral mucositis.

ST supporting Private Cancer Physicians of Australia

ST supporting Private Cancer Physicians of Australia

A haematology career combines cutting edge medicine with a strong focus on people, according to advanced trainee Dr Joel Wight. We profile his "fortuitous" career in the first of a special series ahead of the Private Cancer Physicians of Australia (PCPA) annual conference in Melbourne this weekend, April 29 and 30, 2017. As a company, ST remains committed to advanced trainee education and are proud to be co-sponsoring this prestigious annual meeting.

Endometrial Cancer Trial: Clinical Phase Completed

Endometrial Cancer Trial: Clinical Phase Completed

There is hope that a new therapy will one day be available for women with endometrial cancer, following the completion of the clinical phase of an important Phase 3 study of Zoptrex (zoptarelin doxorubicin). Proceed to Press Release issued by Aeterna Zentaris, Inc.

Oral Mucositis - Expert Opinion, Prof Dorothy Keefe

Oral Mucositis - Expert Opinion, Prof Dorothy Keefe

Internationally regarded mucositis expert Professor Dorothy Keefe says managing this extremely debilitating condition is completely central to managing cancer patients properly.

Call to Screen Type 2 Diabetics for Pancreatic Cancer

Call to Screen Type 2 Diabetics for Pancreatic Cancer

November 21, 2016: Dr Lorraine Chantrill discusses Type 2 diabetes and pancreatic cancer. While no link between these two diseases has been established, Dr Chantrill says tumours can affect normal insulin production and a surprise diabetes diagnosis may sometimes be an early cancer warning.

Sports Broadcaster Takes On New Sporting Challenge

Sports Broadcaster Takes On New Sporting Challenge

October 20, 2016: Specialised Therapeutics Australia (STA) has a particular interest in pancreatic cancer and is committed to supporting efforts to advance understanding and improve clinical outcomes in this disease. Testimony to this commitment, we recently sponsored well-known television personality and sports broadcaster Tiffany Cherry to participate in the GI Cancer Institute’s ‘Gutsy Challenge’ - a seven day cycling challenge across Cambodia to raise awareness and vital funding for Australian research into GI cancers.

Shelli's Story: How Breast Cancer inspired 'Kit for Cancer'

Shelli's Story: How Breast Cancer inspired 'Kit for Cancer'

October 10, 2016: Two and a half years ago, Melbourne based high flyer Shelli Whitehurst was diagnosed with Stage 4 breast cancer. The devastating diagnosis inspired her to found a business that’s now helping other cancer patients around the world.

ICLUSIG™ to be PBS Listed November 1, 2015

ICLUSIG™ to be PBS Listed November 1, 2015

October, 2015: Specialised Therapeutics Australia (STA) is delighted to announce that ICLUSIG™ has received a confirmed listing date of 1 November 2015.

Updated Pancreatic Cancer Data Presented At International Cancer Conference

Updated Pancreatic Cancer Data Presented At International Cancer Conference

January, 2014: A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for patients with metastatic pancreatic cancer when used in combination with current standard of care, gemcitabine, with some patients surviving longer than three years.1

Melbourne Biopharmaceutical Company Named First Corporate Sponsor of International Medical Aid Organisation

Melbourne Biopharmaceutical Company Named First Corporate Sponsor of International Medical Aid Organisation

June, 2013: Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable organisation which enables medical and surgical specialists to impart their expertise to colleagues in developing countries.

ABRAXANE Meets Primary Endpoint of Overall Survival Improvement in Phase III Advanced Pancreatic Cancer Study

ABRAXANE Meets Primary Endpoint of Overall Survival Improvement in Phase III Advanced Pancreatic Cancer Study

November, 2012: Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival.

New Drug To Fight Hospital Superbug Infection

New Drug To Fight Hospital Superbug Infection

June, 2012: A new therapy to treat a common hospital superbug* infection Clostridium difficile, will soon be available to Australian & New Zealand patients.

Royal Melbourne Hospital: First Public Hospital in Australia to Adopt New Technology for Brain Tumour Surgery

Royal Melbourne Hospital: First Public Hospital in Australia to Adopt New Technology for Brain Tumour Surgery

May, 2012: Patients with an aggressive form of brain tumour, glioblastoma multiforme (GBM), have been given access to a new brain tumour visualisation drug, Gliolan® (5-aminolevulinic acid), at The Royal Melbourne Hospital.

First Australian Patients Treated With New Brain Tumour Drug - Gliolan®

First Australian Patients Treated With New Brain Tumour Drug - Gliolan®

September, 2011: Two Australian patients have undergone surgery with the aid of a new drug which assists neurosurgeons to visualise and remove high grade gliomas - brain tumours which typically have a poor prognosis.

Specialised Therapeutics’ Compassionate Program has provided cancer patients access to over $1m of cancer drug, ABRAXANE® since TGA approval

Specialised Therapeutics’ Compassionate Program has provided cancer patients access to over $1m of cancer drug, ABRAXANE® since TGA approval

August, 2010: Hundreds of cancer patients around Australia have had free and subsidised access to a world leading cancer drug, under a compassionate program administered by the family-owned bio-pharmaceutical company which markets the treatment in Australia.

ABRAXANE® in Focus at International Conference

ABRAXANE® in Focus at International Conference

May, 2010: World leading advanced breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) will be in focus at a leading international medical conference in Chicago next week.

Rare Cancers Australia - A focus on less common cancers

Rare Cancers Australia - A focus on less common cancers

Rare Cancers Australia - A focus on less common cancers